a division of NanoInk®,
focuses exclusively on delivering brand protection solutions to fight illegal
diversion and counterfeiting. Anchored by NanoInk's novel NanoEncryption™
technology, NanoGuardian enables manufacturers to authenticate and trace the
integrity of their products across the supply chain, announced a partnership
with SDI, a leader in innovative analytics for the pharmaceutical and healthcare
industries, to deliver its Closed-Loop Protection™ market monitoring program.
Closed-Loop Protection combines the on-dose authentication and tracing benefits
of NanoGuardian's NanoEncryption™ technology with a proactive pharmacy
auditing program to identify counterfeit or illegally-diverted pharmaceuticals
entering the global supply chain.
NanoGuardian's NanoEncryption technology provides on-dose security features
at the overt, covert and forensic level and can be applied directly to tablets,
capsules and vial caps. These multi-layered security features enable NanoGuardian
to provide a dual-protective benefit to manufacturers with a single technology.
The overt and covert security features enable authentication at any point in
the supply chain, while the forensic-level NanoCodes™ provide comprehensive
tracing information on every single dose.
NanoGuardian's NanoCodes can be associated with an unlimited amount of data
including, but not limited to product information (strength, expiration date),
manufacturing information (location, date, batch and lot number), and distribution
information (country, distributor, wholesaler, chain, RFID or 2-D Barcode).
Since NanoGuardian's on-dose protection always remains with the specific dose
even after numerous repackaging efforts, NanoGuardian provides brand integrity,
protection and confidence that standard, on-package, e-pedigree technologies
cannot alone provide.
NanoGuardian's Closed-Loop Protection is a market-monitoring program that works
hand-in-hand with NanoEncryption technology to provide manufacturers an "Early
Warning System" in the detection of counterfeit and diverted product. Through
random audits at retail pharmacies, NanoGuardian's Closed-Loop Protection can
proactively detect counterfeit and diverted product providing manufacturers
with early detection of problems and mitigating risk to brands, companies and
"To ensure the success of Closed-Loop Protection, it was vital to partner
with an organization such as SDI, that has the regulatory experience in conducting
proactive market monitoring services and that can manage networks of pharmacies
and physicians," said Dean Hart, executive vice president, NanoGuardian.
"With Closed-Loop Protection, we can proactively identify costly counterfeiting
and illegal diversion activities as they occur, which allows more time for action
and reduces the risk to pharmaceutical companies and patients."
"We are excited to partner with NanoGuardian in combining SDI's strong
market research resources with NanoGuardian's on-dose NanoEncryption technology
to better enable manufacturers to protect patients by ensuring supply chain
integrity," said Andrew Kress, CEO, SDI.
According to the U.S.-based Centre for Medicines in the Public Interest (CMPI),
counterfeit drug commerce is estimated to grow 13 percent annually through 2010.
"That means counterfeit drug sales will grow at nearly twice the rate of
legitimate pharmaceutical commerce," states Peter Pitts, President of CMPI.
"In 2010, this illegal business will generate $75 billion in revenues --
a 92 percent increase from 2005."